Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrative genomic and bioinformatic prioritization of drug repurposing candidates for prostate cancer.

BMC pharmacology & toxicology - 5 Aug 2025

Irham Lalu Muhammad, Adikusuma Wirawan, Afief Arief Rahman, Khairi Sabiah, Chong Rockie, Mufidah Syarifatul, Satria Rahmat Dani, Mugiyanto Eko, Darmawi Darmawi, Amukti Danang Prasetyaning, Wirsahada Brilliant Citra, Philothra Petrina Theda, Jaya Indra

Abstract excerpt

OBJECTIVE: Prostate cancer remains a prevalent global health challenge, with limited treatment options for advanced stages. There is a critical need to identify effective therapies through systematic integration of genomic and biological data. METHODS: We analyzed 10,911 single nucleotide polymorphisms (SNPs) in 554 genes from genome- and phenome-wide association studies to identify biological risk genes for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Computational Biology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Repositioning

Share to AR gene

Share to Genomics

Share to Molecular Docking Simulation

Share to Polymorphism, Single Nucleotide

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 40764606
DOI: 10.1186/s40360-025-00983-3
PMCID: PMC12326658

Genes

ESR2
MAP2K1
AR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrative genomic and bioinformatic prioritization of drug repurposing candidates for prostate cancer.PMID 40764606Read ↗

Bioinformatics and system biology approaches for identifying potential therapeutic targets for prostate cancerSemantic proximity Read ↗

Identifying Potential Drug Targets for Prostate Cancer from a Genetic Perspective: A Mendelian Randomization StudySemantic proximity Read ↗

Multi-omics association study identifies new potential prostate cancer- causing geneSemantic proximity Read ↗

Druggable Genome-Wide Mendelian Randomization Identifies Therapeutic Targets and DNA Methylation-Mediated Regulation in Urological Malignancies.Semantic proximity Read ↗

In silico exploration of anti-prostate cancer compounds from differential expressed genesSemantic proximity Read ↗

Identification of Differentially Expressed Genes and Drug Targets in Prostate Cancer Using Next-Generation SequencingSemantic proximity Read ↗

Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.Semantic proximity Read ↗

curatedPCaData: Integration of clinical, genomic, and signature features in a curated and harmonized prostate cancer data resourceSemantic proximity Read ↗

Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer.Semantic proximity Read ↗

Shared genetics between breast cancer and predisposing diseases identifies novel breast cancer treatment candidatesSemantic proximity Read ↗

Shared genetics between breast cancer and predisposing diseases identifies novel breast cancer treatment candidates.Semantic proximity Read ↗

From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.